Key facts
- Status: Out of Business.
- ·Watchlist + deal alerts for Singularity Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Singularity Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Singularity Biotech
Developer of universal therapeutics designed for genetic retinal diseases. The company offers retinal organoid production technology to create treatments for various ophthalmic conditions, enabling people to help preserve their vision by addressing the underlying genetic causes of retinal degeneration.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2023
- Employees
- 5
- Website
- singbiotech.com/
- Ownership
- Out of Business
Singularity Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Singularity Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Singularity Biotech in its N-PORT filings yet. We sweep new filings monthly.